Sellas Life Sciences Group
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sellas Life Sciences Group sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Sellas Life Sciences Group: 6 sponsored US clinical trials, 1 recruiting.
Sellas Life Sciences Group sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematologic Malignancies, with 1 trials.
Upper-quartile sponsor footprint
Sellas Life Sciences Group sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
NCT04588922
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
NCT04229979
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
NCT03761914
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
NCT01827137
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
NCT01266083
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
NCT01265433
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Sellas Life Sciences Group pipeline
1 recruiting of 6 indexed (17% open); 4 completed (67%).
Phase mix: 1 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Hematologic Malignancies (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sellas Life Sciences Group: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Sellas Life Sciences Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Sellas Life Sciences Group page
6 registered trials is a research-attention snapshot, not an endorsement of Sellas Life Sciences Group or any single study.
- 1 of Sellas Life Sciences Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hematologic Malignancies is the condition Sellas Life Sciences Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hematologic Malignancies trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sellas Life Sciences Group pipeline card: 6 registered trials from official public datasets.Report a data error.